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Topic development and structuring a systematic review of
diagnostic tests are complementary processes. The goals
of a medical test review are to identify and synthesize
evidence to evaluate the impacts alternative testing
strategies on health outcomes and to promote informed
decisionmaking. A common challenge is that the request
for a review may state the claim for the test ambiguously.
Due to the indirect impact of medical tests on clinical
outcomes, reviewers need to identify which intermediate
outcomes link a medical test to improved clinical out-
comes. In this paper, we propose the use of five principles
to deal with challenges: the PICOTS typology (patient
population, intervention, comparator, outcomes, timing,
setting), analytic frameworks, simple decision trees,
other organizing frameworks and rules for when diag-
nostic accuracy is sufficient.
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“[We] have the ironic situation in which important
and painstakingly developed knowledge often is
applied haphazardly and anecdotally. Such a
situation, which is not acceptable in the basic
sciences or in drug therapy, also should not be
acceptable in clinical applications of diagnostic
technology.”
J. Sanford (Sandy) Schwartz,
Institute of Medicine, 1985
1
Developing the topic creates the foundation and structure of
an effective systematic review. This process includes under-
standing and clarifying a claim about a test (how a test might
be of value in practice) and establishing the key questions to
guide decisionmaking related to the claim. This typically
involves specifying the clinical context in which the test
might be used. Clinical context includes patient character-
istics, how a new test might fit into existing diagnostic
pathways, technical details of the test, characteristics of
clinicians or operators using the test, management options
and setting. Structuring the review refers to identifying the
analytic strategy that will most directly achieve the goals of
the review, accounting for idiosyncrasies of the data.
Topic development and structuring of the review are
complementary processes. As evidence-based practice cen-
ters (EPCs) develop and refine the topic, the structure of the
review should become clearer. Moreover, success at this
stage reduces the chance of major changes in the scope of the
review and minimizes rework. While this paper is intended to
serve as a guide for EPCs, the processes described here are
relevant to other systematic reviewers and a broad spectrum
of stakeholders including patients, clinicians, caretakers,
researchers, funders of research, government, employers,
health care payers and industry, as well as the general public.
This paper highlights challenges unique to systematic
reviews of medical tests. For a general discussion of these
issues as they exist in all systematic reviews, we refer the
reader to previously published EPC methods papers
2,3. This
paper is one of 12 chapters in a JGIM and AHRQ
supplement that address all aspects of preparation of
systematic reviews of diagnostic tests.
COMMON CHALLENGES
The ultimate goal of a medical test review is to identify and
synthesize evidence that will help evaluate the impacts on
health outcomes of alternative testing strategies. Two
common problems can impede achieving this goal. One is
that the request for a review may state the claim for the test
ambiguously. For example, a new medical test for Alz-
heimer’s disease might fail to specify the patients who may
benefit from the test—ranging from the use of the test as a
screening tool among the “worried well” without evidence of
deficit to using it as a diagnostic test in those with frank
impairment and loss of function in daily living. Similarly, the
request for a review of tests for prostate cancer might neglect
to consider the role of such tests in clinical decisionmaking,
such as guiding the decision to biopsy.
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S11Because of the indirect impact of medical tests on clinical
outcomes, a second problem is how to identify which
intermediate outcomes link a medical test to improved
clinical outcomes compared to an existing test. The
scientific literature related to the claim rarely includes direct
evidence, such as randomized controlled trial results, in
which patients are allocated to the relevant test strategies
and evaluated for downstream health outcomes. More
commonly, evidence about outcomes in support of the
claim relates to intermediate outcomes, such as test
accuracy.
PRINCIPLES FOR ADDRESSING THE CHALLENGES
Principle 1: Engage Stakeholders
Using the PICOTS Typology
In approaching topic development, reviewers should
engage in a direct dialogue with the primary requestors
and relevant users of the review (herein denoted “stake-
holders”) to understand the objectives of the review in
practical terms; in particular, investigators should under-
stand the sorts of decisions that the review is likely to
affect. This serves to bring investigators and stakeholders
to a shared understanding about the essential details of
the tests and their relationship to existing test strategies
(i.e., replacement, triage, or add-on), range of potential
clinical utility, and potential adverse consequences of
testing.
Operationally, the objective of the review is reflected in
the key questions, which are normally presented in a
preliminary form at the outset of a review. Reviewers
should examine the proposed key questions to ensure that
they accurately reflect the needs of stakeholders and are
likely to be answered given the available time and
resources. This is a process of trying to balance the
importance of the topic against the feasibility of completing
the review. Including a wide variety of stakeholders (such as
the U.S. Food and Drug Administration [FDA], manufac-
turers, technical and clinical experts, and patients) can help
provide additional perspectives on the claim and use of the
tests. A preliminary examination of the literature can
identify existing systematic reviews and clinical practice
guidelines that may summarize evidence on current
strategies for using the test and its potential benefits and
harms.
The PICOTS typology (Patient population, Intervention,
Comparator, Outcomes, Timing, Setting), defined in the
Introduction to this Medical Test Methods Guide (Chapter
1), is a typology for defining particular contextual issues,
and this formalism can be useful in focusing discussions
with stakeholders. Furthermore, the PICOTS typology is a
vital part of systematic reviews of both interventions and
tests, lending them a transparent and explicit structure and
influencing search methods, study selection and data
extraction.
It is important to recognize that the process of topic
refinement is iterative and PICOTS elements may change as
the clinical context becomes clearer. Despite the best efforts
of all participants, the topic may evolve even as the review
is being conducted. Investigators should consider at the
outset how such a situation will be addressed.
4–6
Principle 2: Develop an Analytic Framework
We use the term “analytic framework” (sometimes called a
causal pathway) to denote a specific form of graphical
representation that specifies a path from the intervention or
test of interest to all important health outcomes, including
intervening steps and intermediate outcomes.
7 Among
PICOTS elements, the target patient population, interven-
tion and clinical outcomes are specifically shown. The
intervention can actually be viewed as a test and treat
strategy as shown in links 2 through 5. In the figure, the
comparator is not shown explicitly, but is implied. Each
linkage relating test, intervention, or outcome represents a
potential key question and, it is hoped, a coherent body of
literature.
The AHRQ EPC program has described the development
and use of analytic frameworks in systematic reviews of
interventions. Since the impact of tests on clinical outcomes
usually depends on downstream interventions, analytic
frameworks for systematic reviews of tests are particularly
valuable and should be routinely included. The analytic
framework is developed iteratively in consultation with
stakeholders to illustrate and define the important clinical
decisional dilemmas and thus serves to clarify important
key questions further.
2
However, systematic reviews of medical tests present
unique challenge not encountered in reviews of therapeutic
interventions. The analytic framework can help users to
understand how the often-convoluted linkages between
intermediate and clinical outcomes fit together, and to
consider whether these downstream issues may be relevant
to the review. Adding specific elements to the analytic
framework will reflect the understanding gained about
clinical context.
Harris and colleagues have described the value of the
analytic framework in assessing screening tests for the U.S.
Preventive Services Task Force (USPSTF).
8 A prototypical
analytic framework for medical tests as used by the
USPSTF is shown in Figure 1. Each number in Figure 1
can be viewed as a separate key question that might be
included in the evidence review.
In summarizing evidence, studies for each linkage might
vary in strength of design, limitations of conduct, and
S12 Samson and Schoelles: Medical Tests Guidance JGIMadequacy of reporting. The linkages leading from changes
in patient management decisions to health outcomes are
often of particular importance. The implication here is that
the value of a test usually derives from its influence on
some action taken in patient management. Although this is
usually the case, sometimes the information alone from a
test may have value independent of any action it may
prompt. For example, information about prognosis that does
not necessarily trigger any actions may have a meaningful
psychological impact on patients and caregivers.
Principle 3: Consider Using Decision Trees
An analytic framework is helpful when direct evidence is
lacking, showing relevant key questions along indirect
pathways between the test and important clinical outcomes.
Analytic frameworks are, however, not well-suited to
depicting multiple alternative uses of the particular test (or
its comparators) and are limited in their ability to represent
the impact of test results on clinical decisions, and the
specific potential outcome consequences of altered deci-
sions. Reviewers can use simple decision trees or flow
diagrams alongside the analytic framework to illustrate
details of the potential impact of test results on management
decisions and outcomes. Along with PICOTS specifications
and analytic frameworks, these graphical tools represent
systematic reviewers’ understanding of the clinical context
of the topic. Constructing decision trees may help to clarify
key questions by identifying which indices of diagnostic
accuracy and other statistics are relevant to the clinical
problem and which range of possible pathways and out-
comes (see Paper 3) practically and logically flow from a
test strategy. Lord et al. describe how diagrams resembling
decision trees define which steps and outcomes may differ
with different test strategies, and thus the important
questions to ask to compare tests according to whether the
new test is a replacement, a triage, or an add-on to the
existing test strategy.
9
One example of the utility of decision trees comes from a
review of noninvasive tests for carotid artery disease.
10 In
this review, investigators found that common metrics of
sensitivity and specificity that counted both high-grade
stenosis and complete occlusion as “positive” studies would
not be reliable guides to actual test performance because the
two results would be treated quite differently. This insight
was subsequently incorporated into calculations of nonin-
vasive carotid test performance.
10,11 Additional examples
are provided in the illustrations below. For further dis-
cussion on when to consider using decision trees, see Paper
10 in this series.
Figure 1. Application of USPSTF analytic framework to test evaluation. Adapted from Harris et al., 2001.
7
S13 Samson and Schoelles: Medical Tests Guidance JGIMFigure 2. Example of an analytical framework within an overarching conceptual framework in the evaluation of breast biopsy techniques
1.
1The numbers in the figure depict where the three key questions are located within the flow of the analytical framework.
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Principle 4: Sometimes it Is Sufficient to Focus
Exclusively on Accuracy Studies
Once reviewers have diagrammed the decision tree by which
diagnostic accuracy may affect intermediate and clinical
outcomes, it is possible to determine whether it is necessary
to include key questions regarding outcomes beyond diag-
nostic accuracy. For example, diagnostic accuracy may be
sufficient when the new test is as sensitive and as specific as
the old test and the new test has advantages over the old test
Table 1. Examples of Initially Ambiguous Claims that were Clarified Through the Process of Topic Development
Full-Field Digital Mammography HER2 PET
General topic FFDM to replace SFM in breast
cancer screening (Fig. 3)
HER2 gene amplification assay as
add-on to HER2 protein expression
assay (Fig. 4)
PETas triage for breast biopsy (Fig. 5)
Initial ambiguous
claim
FFDM may be a useful alternative to
SFM in screening for breast cancer
HER2 gene amplification and protein
expression assays may complement
each other as means of selecting
patients for targeted therapy
PET may play an adjunctive role to
breast examination and
mammography in detecting breast







Key statistics: sensitivity, diagnostic
yield, recall rate; similar types of
management decisions and outcomes
for index and comparator test-and-
treat strategies
Key statistics: proportion of
individuals with intermediate/
equivocal HER2 protein expression
results who have HER2 gene
amplification; key outcomes are
related to effectiveness of HER2-
targeted therapy in this subgroup
Key statistics: negative predictive
value; key outcomes to be
contrasted were benefits of avoiding
biopsy versus harms of delaying
initiation of treatment for
undetected tumors
Refined claim In screening for breast cancer,
interpretation of FFDM and SFM would
be similar, leading to similar
management decisions and outcomes;
FFDM may have a similar recall rate and
diagnostic yield at least as high as SFM;
FFDM images may be more expensive,
but easier to manipulate and store
Among individuals with localized
breast cancer, some may have
equivocal results for HER2 protein
overexpression but have positive
HER2 gene amplification, identifying
them as patients who may benefit
from HER2-targeted therapy but
otherwise would have been missed
Among patients with a palpable breast
mass or suspicious mammogram, if
FDGPETisperformedbeforebiopsy,
those with negative scans may avoid
the adverse events of biopsy with
potentially negligible risk of delayed
treatment for undetected tumor




Seidenfeld et al., 2008
16 Samson et al., 2002
17
Abbreviations: FDG = fluorodeoxyglucose; FFDM = full-field digital mammography; HER2 = human epidermal growth factor receptor 2; PET =
positron emission tomography; PICOTS = Patient population, Intervention, Comparator, Outcomes, Timing, Setting; SFM = screen-film mammographysuch as fewer adverse effects, is less invasive, is easier to use,
provides results more quickly or is lower in cost. Implicit in
this example is the comparability of downstream manage-
ment decisions and outcomes between the test under
evaluation and the comparator test. Another instance when
a review may be limited to evaluation of sensitivity and
specificity is when the new test is as sensitive as, but more
specific than, the comparator, allowing avoidance of harms of
further tests or unnecessary treatment. This situation requires
the assumptions that the same cases would be detected by
both tests and that treatment efficacy would be unaffected by
which test was used.
12,13
Particular questions to consider when reviewing analytic
frameworks and decision trees to determine if diagnostic
accuracy studies alone are adequate include:
1. Are extra cases detected by the new, more sensitive test
similarly responsive to treatment as are those identified by
the older test?
2. Aretrialsavailablethatselectedpatientswiththenewtest?
3. Do trials assess whether the new test results predict
response?
4. If available trials selected only patients assessed with the old
test, do extra cases identifiedw i t ht h en e wt e s tr e p r e s e n t
t h es a m es p e c t r u mo rd i s e a s es ubtypes as trial participants?
5. Are tests’ cases subsequently confirmed by same
reference standard?
6. Does the new test change the definition or spectrum of
disease (e.g., earlier stage)?
7. Is there heterogeneity of test accuracy and treatment
effect (i.e., do accuracy and treatment effects vary
sufficiently according to levels of a patient characteris-
tic to change the comparison of the old and new test)?
Whentheclinicalutilityofanoldercomparatortesthasbeen
established, and the first five questions can all be answered in
the affirmative, then diagnostic accuracy evidence alone may
be sufficient to support conclusions about a new test.
Figure 3. Replacement test example: full-field digital mammography versus screen-film mammography*. * Figure taken from Blue Cross
and Blue Shield Association Technology Evaluation Center, 2002.
14
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Various other frameworks (generally termed “organizing
frameworks,” as described briefly in the Introduction to this
Medical Test Methods Guide [Paper 1]) relate to categorical
features of medical tests and medical test studies. Lijmer
and colleagues reviewed the different types of organiza-
tional frameworks and found 19 frameworks, which
generally classify medical test research into 6 different
domains or phases, including technical efficacy, diagnostic
accuracy, diagnostic thinking efficacy, therapeutic efficacy,
patient outcome, and societal aspects.
13
These frameworks serve a variety of purposes. Some
researchers, such as Van Den Bruel and colleagues, consider
frameworks as a hierarchy and a model for how medical
tests should be studied, with one level leading to the next
(i.e., success at each level depends on success at the
preceding level).
14 Others, such as Lijmer and colleagues
have argued that “The evaluation frameworks can be useful
to distinguish between study types, but they cannot be seen
as a necessary sequence of evaluations. The evaluation of
tests is most likely not a linear but a cyclic and repetitive
process.”
13
We suggest that rather than being a hierarchy of evidence,
organizational frameworks categorize key questions and
suggest which types of studies would be most useful for the
review. They may guide the clustering of studies; this may
improve the readability of a review document. No specific
framework is recommended, and indeed the categories of
most organizational frameworks at least approximately line
up with the analytic framework and the PICO(TS) elements
as shown in Figure 2.
Illustrations
To illustrate the principles above, we describe three
examples. In each case, the initial claim was at least
somewhat ambiguous. Through the use of the PICOTS
typology, the analytic framework, and simple decision trees,
the systematic reviewers worked with stakeholders to clarify
the objectives and analytic approach (Table 1). In addition
to the examples described here, the AHRQ Effective Health
Care Program website (http://effectivehealthcare.ahrq.gov/)
offers free access to ongoing and completed reviews,
containing specific applications of the PICOTS typology
and analytic frameworks.
The first example concerns full-field digital mammogra-
phy (FFDM) as a replacement for screen-film mammogra-
phy (SFM) in screening for breast cancer; the review was
conducted by the Blue Cross and Blue Shield Association
Technology Evaluation Center.
15 Specifying PICOTS ele-
ments and constructing an analytic framework were
straightforward, with the latter resembling Figure 2 in form.
In addition, with stakehoder input a simple decision tree
was drawn (Fig. 3) which revealed that the management
Figure 4. Add-on test example: HER2 protein expression assay followed by HER2 gene amplification assay to select patients for HER2-
targeted therapy*. Abbreviation: HER2 = human epidermal growth factor receptor 2. * Figure taken from Seidenfeld et al., 2008.
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S16 Samson and Schoelles: Medical Tests Guidance JGIMdecisions for both screening strategies were similar, thus
downstream treatment outcomes were not a critical issue.
The decision tree also showed that the key indices of test
performance were sensitivity, diagnostic yield, and recall
rate. These insights were useful as the project moved to
abstracting and synthesizing the evidence, which focused on
accuracy and recall rates. In this example, the reviewers
concluded that FFDM and SFM had comparable accuracy
and led to comparable outcomes; however, storing and
manipulating images was much easier for FFDM than for
SFM.
The second example concerns use of the human
epidermal growth factor receptor 2 (HER2) gene amplifica-
tion assay after the HER2 protein expression assay to select
patients for HER2-targeting agents as part of adjuvant
therapy among patients with localized breast cancer.
16 The
HER2 gene amplification assay has been promoted as an
add-on to the HER2 protein expression assay. Specifically,
individuals with equivocal HER2 protein expression would
be tested for amplified HER2 gene levels; in addition to
those with increased HER2 protein expression, patients with
elevated levels by amplification assay would also receive
adjuvant chemotherapy that includes HER2-targeting
agents. Again, PICOTS and an analytic framework were
developed, establishing the basic key questions. In addition,
the authors constructed a decision tree (Fig. 4) that made it
clear that the treatment outcomes affected by HER2 protein
and gene assays were at least as important as the test
accuracy. While in the first case, the reference standard was
actual diagnosis by biopsy, here the reference standard is the
amplification assay itself. The decision tree identified the
key accuracy index as the proportion of individuals with
equivocal HER2 protein expression results who have
positive amplified HER2 gene assay results. The tree
exercise also indicated that one key question must be
whether HER2-targeted therapy is effective for patients who
had equivocal results on the protein assay but were
subsequently found to have positive amplified HER2 gene
assay results.
The third example concerns use of fluorodeoxyglucose
positron emission tomography (FDG PET) as a guide to the
decision to perform a breast biopsy on a patient with either
Figure 5. Triage test example: positron emission tomography (PET) to decide whether to perform breast biopsy among patients with a
palpable mass or abnormal mammogram*. * Figure taken from Samson et al., 2002.
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17 Only
patients with a positive PET scan would be referred for
biopsy. Table 1 shows the initial ambiguous claim, lacking
PICOTS specifications such as the way in which testing
would be done. The analytic framework was of limited
value as several possible relevant testing strategies were not
represented explicitly in an analytic framework. The authors
constructed a decision tree (Fig. 5). The testing strategy in
the lower portion of the decision tree entails performing
biopsy in all patients, while the triage strategy uses a
positive PET finding to rule in a biopsy and a negative PET
finding to rule out a biopsy. The decision tree illustrates that
the key accuracy index is negative predictive value: the
proportion of negative PET results that are truly negative.
The tree also reveals that the key contrast in outcomes
involves any harms of delaying treatment for undetected
cancer when PET is falsely negative versus the benefits of
safely avoiding adverse effects of the biopsy when PET is
truly negative. The authors concluded that there is no net
beneficial impact on outcomes when PET is used as a triage
test to select patients for biopsy among those with a
palpable breast mass or suspicious mammogram. Thus,
estimates of negative predictive values suggest that there is
an unfavorable trade-off between avoiding the adverse
effects of biopsy and delaying treatment of an undetected
cancer.
This case illustrates when a more formal decision analysis
may be useful, specifically when new test has higher
sensitivity but lower specificity than the old test, or vice
versa. Such a situation entails tradeoffs in relative frequencies
of true positives, false negatives, false positives, and true
negatives, which decision analysis may help to quantify.
SUMMARY
The immediate goal of a systematic review of a medical test
is to determine the health impacts of use of the test in a
particular context or set of contexts relative to one or more
alternative strategies. The ultimate goal is to produce a
review that promotes informed decisionmaking.
Key points are:
& Reaching the above-stated goals requires an interactive
and iterative process of topic development and refinement
aimed at understanding and clarifying the claim for a test.
This work should be done in conjunction with the
principal users of the review, experts, and other stake-
holders.
& The PICOTS typology, analytic framework, simple decision
trees, and other organizing frameworks are all tools that can
minimize ambiguity, help identify where review resources
should be focused, and guide the presentation of results.
& Sometimesit is sufficient tofocusonlyon accuracy studies.
For example, diagnostic accuracy may be sufficient when
the new test is as sensitive and specific as the old test and
the new test has advantages over the old test such as fewer
adverse effects, is less invasive, is easier to use, provides
results more quickly or is lower in cost.
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